ACE2angiotensin-converting enzyme 2

[키워드] and Blood Institute Asthma and Clinical Immunology Asthma and Immunology AAAAIAmerican Academy of Allergy absence ACAAIAmerican College of Allergy ACE2angiotensin-converting enzyme 2 ADCCAntibody-Dependent Cell-mediated Cytotoxicity administration adverse events AEsAdverse events Affect American Academy of Allergy American College of Allergy angiotensin-converting enzyme 2 antibody-dependent cell-mediated cytotoxicity Asthma authority British Thoracic Society BTSBritish Thoracic Society clinician coronavirus Coronavirus disease 2019 COVID-19 COVID-19 in patient COVID-19 pandemic COVID-19coronavirus disease 2019 Deoxyribonucleic acid DNADeoxyribonucleic acid EBMEvidence Based Medicine effective ELFEuropean Lung Foundation ERSEuropean Respiratory Society European Lung Foundation European Respiratory Society Evidence Based Medicine FDAFood and Drug Administration Food and Drug Administration GINAGlobal Initiative for Asthma Glaxo Smith Kline Global Initiative for Asthma GSKGlaxo Smith Kline help ICSinhaled corticosteroids ICUIntensive Care Unit IgEImmunoglobulin E IL13Interleukin 13 IL4Interleukin 4 IL5Interleukin 5 IL5RaInterleukin 5 alfa receptor IL5rInterleukin 5 receptor IL6Interleukin 6 Immunoglobulin E indicated inhaled corticosteroids intensive care unit Interleukin 13 Interleukin 4 Interleukin 5 Interleukin 5 alfa receptor Interleukin 5 receptor interleukin 6 Italian Society of Allergy lung mAbMonoclonal antibody maintain managing medication monoclonal antibody National Heart NHLBINational Heart OCSOral corticosteroids Oral corticosteroids pandemic Patient PDGFRAPlatelet-Derived Growth Factor Receptor A physician Platelet-Derived Growth Factor Receptor A Preventative Omalizumab or Step-up therapy for fall Exacerbations study PROSE studyPreventative Omalizumab or Step-up therapy for fall Exacerbations study question Randomized controlled trials RCTsrandomized controlled trials recommendation SAEsSerious Adverse Events SARPSevere Asthma Research Programme SARS-CoV-2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 SCSubcutaneous Serious Adverse Events severe acute respiratory syndrome coronavirus 2 Severe Asthma Research Programme SIAAICItalian Society of Allergy Subcutaneous supported T2Type 2 inflammation the patient therapy TMPRSS2Transmembrane Protease Serine 2 Enzyme Transmembrane Protease Serine 2 Enzyme treated Type 2 inflammation underlying diseases United States of America USAUnited States of America
[DOI] 10.1016/j.waojou.2020.100126 [Article Type] Review article